Biotech Values

[DewDiligence]

Effient was expected to be a blockbuster, but in its first three quarters on the market sales have totaled just $35 million. By contrast, Plavix, sold by Bristol-Myers Squibb and Sanofi Aventis, has billions of dollars in annual sales.

Plavix is currently outselling Effient by almost 200:1, which is as lopsided as any “competition” I can think of in the drug/biotech industry.

Mr. Schaefer of Lilly, who said Effient sales were improving, said the [Accumetrics diagnostic] collaboration was not aimed at Plavix…

LOL